alicaforsen
Nucleic acidexperimental
Alicaforsen is an antisense oligonucleotide therapeutic that targets the messenger RNA for the production of human ICAM-1 receptor and is being developed for the treatment of acute disease flares in moderate to severe Inflammatory Bowel Disease (IBD). — Wikipedia
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Sep 1, 2001 (NCT00048113)
Timeline
Indications
Mechanism of action
- Intercellular adhesion molecule-1 mRNA 3'UTRANTISENSE INHIBITOR
Intercellular adhesion molecule-1 mRNA 3'UTR antisense inhibitor
- Intercellular adhesion molecule-1INHIBITOR
ICAM1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAlicaforsen ↗
- ChEMBLCHEMBL2108326 ↗
Also known as
- alicaforsen
- alicaforsen
- alicaforsen
- alicaforsen
- alicaforsen sodium
- isis 2302
- isis-2302
- mk-8435
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03473626 | Phase 1 | Mar 16, 2018 | Atlantic Pharmaceuticals Ltd |
| NCT02525523 | Phase 3 | Dec 3, 2015 | Atlantic Pharmaceuticals Ltd |
| NCT00725075 | Phase 2 | Apr 1, 2007 | Merck |
| NCT00063830 | Phase 2 | Jul 7, 2003 | Ionis Pharmaceuticals, Inc. |
| NCT00063414 | Phase 2 | Jun 25, 2003 | Ionis Pharmaceuticals, Inc. |
| NCT00048295 | Phase 3 | May 1, 2002 | Ionis Pharmaceuticals, Inc. |
| NCT00048113 | Phase 3 | Sep 1, 2001 | Ionis Pharmaceuticals, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | For profit | 4 | 4 | 2 | 2001 |
| Atlantic Pharmaceuticals Ltd | For profit | 2 | 2 | 2 | 2015 |
| Merck | For profit | 1 | 1 | 1 | 2007 |
3 organizations
Page 1 / 1